IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection shows promise for kidney disease in early trial
Disease control Not yet recruitingThis study tests a new drug, CM313, in 106 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and helps control the disease. Participants must have had a kidney biopsy confirming the condition and be on standard care. The study is not yet recrui…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Not yet recruitingThis study tests a drug called atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage, over 36 weeks. Participants must have moderate …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New hope for kidney disease: JADE101 trial launches
Disease control Not yet recruitingThis study tests a new drug called JADE101 in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, which is a sign of kidney damage. Participants must be on stable standard treatment before joining.
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Jade Biosciences, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
New study tracks kidney drug use in real life
Knowledge-focused Not yet recruitingThis study will follow 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan in routine care. Researchers will collect data on patient characteristics, treatment patterns, and kidney health over 24 months. The goal is to learn how these drugs work in real-worl…
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:51 UTC